The tools are good enough to build a business around. The business plan, as drafted, is not good enough to bet the tools on yet.
Three fatal flaws must be fixed before a dollar is committed. Six conditions must be met. One open question (Wall Ortho IP) determines whether the business can exist at all.
These must be resolved before any money is spent on domains, LLC formation, or branding.
What the proposal says: practiceaxis.com is a mental health CRM in a different space. "Medium risk, mitigable."
Reality: practiceaxis.com is an active, HIPAA-compliant mental health CRM with a professional brand, logo, blog, and Webflow site. Both companies sell B2B healthcare services to clinical practice owners. A prospective orthodontist googling "Practice Axis" will land on a therapist CRM homepage — trust destroyed before the sales call begins.
In a market of only 2,728 practices, word-of-mouth and Google search are the marketing plan (Phase 3, Section 8). You cannot build organic search authority on a name already indexed for a different healthcare vertical. This is high risk, not medium.
Recommendation: modelortho.com is available. It's descriptive, ortho-specific, memorable, and the .com is free. Two syllables that say exactly what the product does: "we model your ortho practice." A $50 domain decision that avoids a five-figure rebrand in year 2.
Alternative names ranked:
What the proposal says: Section 11 lists "IP separation from Wall Ortho tools" as one of five "Immediate Decisions Required."
Reality: Anita built Schedule Builder and Feasibility Tool while employed at Wall Orthodontics, using Wall Orthodontics' actual appointment data (~13,000+ appointments/year). Depending on her employment agreement:
Recommendation: Obtain a written opinion from an employment attorney before spending a single dollar on domains, LLC formation, or branding. This is a gate, not a parallel-track item. If the opinion comes back unfavorable, the venture is compromised.
What the proposal says: Section 10 P&L shows $240/month fixed burn. "Break-even on first diagnostic client."
Reality: Missing costs that are non-optional for a solo consultant selling into healthcare:
| Missing Cost | Annual Estimate | Monthly |
|---|---|---|
| E&O / professional liability insurance | $1,500 – $3,000 | $125 – $250 |
| Bookkeeper + CPA (tax prep) | $2,000 – $4,000 | $167 – $333 |
| Conference travel (AAO + regional, per event) | $2,000 – $4,000 | $167 – $333 |
| Tool maintenance, hosting, backups | $600 – $2,400 | $50 – $200 |
| Health insurance (leaving W-2 employment) | $4,800 – $9,600 | $400 – $800 |
| CRM / proposal software / website hosting | $500 – $1,500 | $42 – $125 |
| Legal (beyond one-time contract setup) | $500 – $2,000 | $42 – $167 |
| Total Realistic Burn | $11,900 – $26,500 | $993 – $2,208 |
The model still works at $205K revenue — margins remain strong. But the "risk-free, break-even on first client" framing is wrong and undermines credibility with anyone who does the math.
Phase 2 (Section 8) assumes "2-3 orthodontists from Anita's professional network" are ready to pay. After 20 years at a single practice, her network is likely deep with Wall Ortho's vendors and reps — not necessarily decision-making practice owners. Name the contacts. Get actual willingness-to-pay signals before finalizing the Phase 2 timeline.
The proposal describes Schedule Builder and Feasibility Tool repeatedly — but there is no screenshot, no sample output, no demo. The Growth Feasibility Report (the core $5K deliverable) doesn't exist as a sample artifact. Sell the artifact, not the description of the artifact. Every prospective client will ask "show me what I'm buying."
All validation is N=1 — a single practice where Anita had 20 years of institutional trust and free data access. The tools were built against one practice's scheduling patterns. Orthodontic practices vary dramatically in provider mix, patient volume, deband ratios, and PMS software. Run a friends-and-family beta with at least one different practice before charging full price. If the model doesn't generalize, the first few paid engagements become unpaid beta tests — and that's how you torch the testimonials Phase 2-3 depend on.
This is the single largest unaddressed execution risk in the entire document. Anita's 20-year track record is operations coordination — internal execution, process, analytical rigor. Every projected dollar depends on her becoming an effective B2B closer of $3,500-$5,000 deals by month 3, with zero demonstrated sales experience and zero training budget. Three options:
The proposal positions Gaidge as "just benchmarking" (Section 4). Independent research confirms they have named consultants (Jessica Bryson, Stacey Bybee, Andrea) running an active 360 Consulting arm on top of an analytics platform with hundreds of existing practice clients. They are already at the data + advisory intersection Practice Axis claims as unique. The realistic competitive threat is not a startup copying the tools — it's Gaidge adding a capacity modeling module to their existing platform, with an existing sales channel and existing client trust. They don't start from zero.
AAO Annual Session speaker slots for a first-time, unpublished consultant is a 12-24 month milestone, not a 5-12 month one. AAO's speaker selection process requires established conference history, sponsor/co-presenter credibility, or submission to a call-for-papers cycle with long lead times. Including this as a Year 1 success metric damages the credibility of every other projection by association. Replace with: "Submitted 2+ conference speaking proposals" or "1 regional study club presentation."
| Area | Finding | Severity |
|---|---|---|
| Pricing | Too conservative. $4,997 Diagnostic should be $7,500-9,997. $2,497/mo Partnership should be $3,500-4,000/mo. Pricing below competitors while claiming superior differentiation. | Medium |
| Founding Partner Discount | 30% off is too deep. $4,997 becomes $3,498 — at exactly the moment Anita has zero case studies and needs pricing power the LEAST. Discount via added scope, not price cuts. First price anchors are sticky. | High |
| TAM Realism | 2,728 practices is the ceiling. The real buying trigger is "actively facing a growth/hiring decision in next 12 months" — a fraction of the 409-546 practices cited. The proposal doesn't segment for active growth decisions vs. stable practices. | Medium |
| DSO Consolidation | Rated "Medium/Medium" risk but it's structural: every sold practice stops being a prospect. The pie is shrinking, not growing. Expansion Advisory tier (targeting DSO-bound practices) is a different, smaller, higher-touch motion. | Medium |
| Sales Motion | No sales script, objection-handling playbook, warm-intro strategy, or paid acquisition test budget. The entire growth engine is "direct outreach" and "referrals" by a first-time solo founder. Largest unaddressed execution risk. | High |
| SEO Timeline | Phase 3 SEO doesn't start until month 5. Meaningful organic traffic realistically arrives month 11-17. Should not be load-bearing for Year 1 revenue. | Medium |
| Solo Founder Fragility | No redundancy. One flu season or family emergency during Phase 2 stalls the entire pipeline. No contingency plan, no locum, no partner. | High |
| Client Data / PHI | Receiving raw schedule exports from practice management systems raises HIPAA-adjacent concerns. No BAA or data security posture addressed. | Medium |
| PMS Compatibility | Does Schedule Builder ingest from Dolphin, OrthoTrac, Cloud9, etc. or is every client a manual data entry job? This determines whether 99% gross margin holds. | Medium |
| N=1 Validation | All tool validation is against a single practice with ~13,000 appointments/year. Different practices have different scheduling patterns, provider mixes, and PMS platforms. First few paid engagements are effectively beta-test risk. | High |
Section 1 (Executive Summary): Strong. The "four constraints nobody models" is the single best paragraph in the document. Lead with that everywhere.
Section 3 (Problem Statement): Excellent. The cascading-appointment-load dynamic is a real structural insight that separates ortho from general dental consulting. This is the core of the pitch.
Section 4 (Market Analysis): Competitive table is too thin. One-line descriptions don't capture Gaidge's consulting arm or CascadEffects' sophistication. Weakens the positioning claims when competitors are under-described.
Section 5 (Product Overview): Service architecture is clear. But there's zero visual evidence of the tools. Add screenshots. Add a redacted sample report.
Section 6 (Revenue Model): Tier structure is directionally right. Pricing is directionally low. Founding Partner 30% discount is the wrong mechanism at the wrong time.
Section 7 (Moat): The four moat pillars are overclaimed. The real moat is Anita's specific operational fluency + the tools as evidence of credibility, not an unassailable technology barrier.
Section 8 (GTM): The weakest section. Vague network assumptions. Unrealistic conference speaking timeline. No paid acquisition test. No sales script or objection handler. All execution risk, no de-risking.
Section 9 (Risk): Three named risks are real but secondary. The three risks that actually threaten this business (IP ownership, solo-founder fragility, N=1 validation) are missing.
Section 10 (Financials): Directionally plausible at the top line. Burn rate is substantially understated. The model still works — just be honest about it.
Section 11 (The Ask): Reasonable startup costs ($1,240-3,550). Domain name analysis underweights the practiceaxis.com collision.
This is a real business with a real founder and a real product, sitting behind one unanswered legal question and one unproven validation claim. Answer those two, and it's a go. Skip them, and it's a lawsuit with a logo.
Signed — Conductor, Claude Opus 4.8, Phase 3 Final Assessment
Sonnet listed the name as fatal flaw #1 and IP ownership as #2. That ordering is backwards and dangerous.
IP is the sole hard gate — the only item that can retroactively destroy the entire business. A brand collision costs you SEO. An IP claim costs you the business and possibly a lawsuit. The PHI-in-the-tools angle upgrades this from "ownership dispute" to "possible data misappropriation" — a categorically more serious legal posture.
The name (Practice Axis → ModelOrtho) is a must-do, not a gate. It's the most fixable flaw — costs $0 and a weekend at this pre-launch stage — not the most fatal.
Sonnet correctly diagnosed that Anita has zero sales experience and the plan depends on her becoming an effective B2B closer by month 3. But prescribing a sales co-founder (20-40% equity) as a condition is unrealistic given: (a) a good B2B healthcare sales co-founder is hard to recruit into a pre-revenue micro-market of 2,728 practices, and (b) you don't hand equity before proving the tools work on one clean-data client.
Replaced with: Warm-only GTM — no cold outreach in Year 1. Anita's advantage is credibility, not hunting ability. She sells via warm demos into validated network contacts. If she needs help, fractional/commission-based BD advisor — no equity given away pre-validation.
Sonnet listed "test tools against non-Wall-Ortho practice" as Condition 3. It's actually the single highest-leverage action in the entire review. One pilot simultaneously: (a) kills the N=1 validation problem, (b) de-risks the IP position (proves tools work on clean data), and (c) generates the first case study. Three problems, one action.
Sonnet produced 3 fatal flaws + 6 conditions. Opus re-structured them into a gated, sequential pipeline:
G0. Wall Ortho IP + data + non-compete clearance. Nothing proceeds until this is closed in writing. No spend, no rebrand, no outreach until resolved.
Approach as a partnership conversation first — a friendly, lawyer-drafted release letter framed as "confirming my personal tools are mine to keep." Given 20 years of goodwill, this may cost a coffee and a signature. If they refuse, she's in clean-room-rebuild territory. Better to know on day one.
Her 20-year employer is also her most credible first reference, pilot host, and referral source. If the IP question is approached adversarially (lawyer letter cold), she may poison a relationship that could be her single best go-to-market asset. Sequence it as a partnership conversation first, legal instrument second.
In a 2,728-practice market, orthodontists talk. If Wall Ortho perceives her as "took our tools and now sells to our competitors," word travels through exactly the small-market word-of-mouth channel the proposal identified as the entire marketing plan. The IP resolution must protect reputation, not just legality.
Two proprietary tools mean she is now a solo software vendor — versioning, bug fixes, PMS-integration breakage when Dolphin/Cloud9 update exports, and client support. Every hour debugging Schedule Builder is an hour not selling or delivering. For a solo founder, this is a hidden time-tax that compounds fragility.
The model caps at ~$300-500K/year for a solo consultant doing high-touch work. That's a great lifestyle practice, not a company. Germaine and Anita should decide on purpose which they're building — the two require different everything.